Plain-English translation of NCT04150497 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which uses specially engineered immune cells to fight a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL) that has come back or stopped responding to standard chemotherapy. The study will determine the safest and most effective dose of this medication. Researchers will carefully watch how well the treatment works and what side effects patients experience.
Patients whose leukemia returns after initial treatment or stops responding to chemotherapy have very limited options and face poor outcomes. This trial exists to develop a new approach using the body's own immune system to fight back against this aggressive cancer, potentially offering hope to patients who have run out of standard treatment choices.
You likely qualify if…
You likely don't qualify if…
You will receive an intravenous infusion (injection into your vein) of the engineered cells at the hospital or clinic. The trial starts by testing different doses to find the safest and most effective amount; depending on which group you join, you may receive a lower or higher dose. After receiving the infusion, you will have regular follow-up visits and blood tests to monitor how your body responds, watch for any side effects, and measure whether your leukemia is improving.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States